Key result
Elevated markers of thrombin generation, particularly prothrombin fragment 1.2 (F1.2), were associated with the development of venous thromboembolism in adult cancer patients.
Why the study?
Venous thromboembolism is a major contributor to morbidity and mortality in cancer, and biomarkers such as thrombin generation markers are continually sought to predict cancer-associated VTE.
Do markers of thrombin generation (F1.2, TAT, ex vivo thrombin generation) predict the development of venous thromboembolism in adult cancer patients?
Population
Adult solid and hematologic cancer patients across 24 included papers
Comparison
Predictive ability of F1.2, TAT, and ex vivo thrombin generation for VTE
Design
Systematic review
Authors
Loading...
May refine cancer VTE risk stratification via F1.2; extends systematic evidence on thrombin generation markers.
Systematic Review
Do markers of thrombin generation (F1.2, TAT, ex vivo thrombin generation) predict the development of venous thromboembolism in adult cancer patients?
Thrombin generation markers, particularly F1.2, are promising predictors of cancer-associated VTE and may improve the precision of established risk assessment scores.
Gyldenholm et al. (2023) conducted a systematic review in Cancer-associated venous thromboembolism. Elevated thrombin generation markers (F1.2, TAT, ex vivo thrombin generation) vs. Normal or lower levels of thrombin generation markers was evaluated on Development of venous thromboembolism (VTE). Elevated markers of thrombin generation, particularly prothrombin fragment 1.2 (F1.2), were associated with the development of venous thromboembolism in adult cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: